A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.
Also called NCT06323174
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 189 participants
- Sponsor
- Registry
-
NCT06323174
-
- Other papers using this trial's data
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, China, Hungary, Italy, Poland, Saudi Arabia, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT06323174. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-19 (actual); primary completion 2025-10-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- Acronym
- REIMAGINE 1
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06323174- Content hash
891234b453a8e4a1a17b0d416c27e50a8a04fd2affa1ba6afc8cdbf32b0bcea8